#USA #Mequon #Therapeutics #Vector Science #Transdermal Delivery

Vector Science & Therapeutics Reveals a Groundbreaking Transdermal Peptide Delivery System

Vector Science & Therapeutics Corp., a company based in Mequon, Wisconsin, has recently taken a significant step in advancing peptide medicine by filing a provisional patent for its innovative wearable transdermal delivery platform. This platform utilizes an ingenious pulsed magnetic field technology that enables the administration of peptide therapeutics directly through the skin, eliminating the need for traditional methods such as injections, needles, or electrical stimulation.

Tackling a Longstanding Challenge

One of the primary hurdles in peptide medicine has been the difficulty in effectively delivering therapeutic molecules past the skin barrier to the affected tissues. The newly developed platform addresses this challenge by employing a proprietary magnetic patch that guides microscopic peptide carriers through the various layers of the skin to precisely reach the target site. Once the carriers arrive at their destination, they are designed to release their therapeutic payload solely when they encounter biological signals associated with disease or inflammation, thereby safeguarding the surrounding healthy tissue.

A noteworthy aspect of this advanced platform is its built-in mechanism for confirming successful delivery. Both clinicians and patients can verify that the peptides have reached their intended location through real-time imaging as well as a color-changing indicator integrated into the patch, which responds accordingly to the successful release of the therapeutic agents. Additionally, the carriers are crafted to exit the body naturally within a 72-hour timeframe, effectively addressing potential safety concerns typically associated with nanoparticle-based therapies.

Broad Applications Across Medical Conditions

Vector's new delivery platform is designed for a wide range of applications, particularly concerning conditions characterized by tissue inflammation, degeneration, or injury. This aligns with the company's commitment to providing non-invasive and non-systemic interventions in the realms of musculoskeletal and regenerative medicine. Furthermore, the new delivery technology is set to be formulated at the LyoGenesis Plus manufacturing facility located in Mequon, Wisconsin, as part of a manufacturing partnership agreement.

Bill Jackson, the Chief Executive Officer of Vector Science & Therapeutics, expressed optimism about the filing of this provisional patent, stating, "This establishes the intellectual property foundation for what we believe will be a significant clinical advance. We view this as a breakthrough technology and are keen to pursue De Novo marketing authorization through expedited access pathways and priority reviews."

The recent patent filing enhances Vector's already growing intellectual property portfolio, which now encompasses a total of 15 patents focusing on non-invasive transdermal drug and peptide delivery. This includes the recently filed hybrid phoresis platform aimed at delivering BPC-157 and TB-500 solutions to targeted musculoskeletal and peripheral nerve areas, extending its reach to areas like post-operative pain management, wound healing, and specialized electrochemotherapy. These developments exemplify Vector's dedication to establishing a proprietary, multifaceted foundation for localized, non-systemic therapeutic delivery.

As part of keeping its progress on the radar, the company is attentively monitoring the upcoming FDA Pharmacy Compounding Advisory Committee meeting set for July 23-24, 2026. This meeting is anticipated to address the regulatory status of various peptides, including BPC-157 and TB-500, which are relevant to Vector's innovative delivery platforms.

About Vector Science & Therapeutics Corp.

Headquartered in Mequon, Wisconsin, Vector Science & Therapeutics Corp. is at the forefront of developing cutting-edge biomechanical devices and localized drug delivery systems. These innovations are designed to equip healthcare professionals with precise intervention tools where systemic risks are too high. The company's shares are traded on the TSX Venture Exchange with the symbol PAIN. For more details, visit www.vectorscience.co.

A Look Ahead

The trajectory of Vector Science & Therapeutics in the biotechnology sector illustrates their commitment to pioneering solutions that enhance therapeutic delivery processes. As they continue to innovate, the impact of their advancements on the medical landscape is expected to be profound, offering patients more effective, targeted treatment options without the discomfort and risks associated with traditional delivery methods. The future looks bright as they navigate the path toward regulatory approvals and further technological refinements.